MEA Liquid Biopsy Market

MEA Liquid Biopsy Market Size (2023 to 2028)

The Middle East and Africa liquid biopsy market is expected to grow at a CAGR of 21.71% during the forecast period. As a result, the market size is predicted to value USD 513.95 million by 2027 from USD 192.28 million in 2023.

A liquid biopsy helps collect a wide range of information about cancer/tumors through a simple blood sample. For example, the procedure can help detect mutations in epidermal growth factor receptors in cancers. Liquid biopsies are also helpful in residual cancer detection, which can be performed with 5 milliliters of blood to detect the present metastases in various tumors.

Liquid biopsy is a minimally invasive technique to analyze the non–solid biological tissues, mostly for early cancer detection. According to WHO, the number of cancer patients in the Middle East is increasing every year; according to WHO, the number will double by 2030. Over 70% of deaths in the Middle East are due to cancer. According to WHO, 9 out of 22 countries in the Middle East do not have operational facilities for cancer treatment. Thus, the demand for liquid biopsy is increasing in this region as a liquid biopsy can be used to detect cancer. In addition, liquid biopsy is less painful than a traditional tissue biopsy. The government in this region is giving funds for the development of liquid biopsy to improve the health care service in this region. Inivata, a leading company in liquid biopsy, has signed a distribution agreement with IPS Genomix to provide InVisionFirst and InVisionSeq liquid biopsy tests in the Middle East and Africa. 

The growing prevalence of improving healthcare infrastructures across the region is mainly propelling the market's growth rate. Furthermore, the rise in the incidences of life-threatening diseases is also elevating the market's growth rate. In addition, the rising number of cancer patients globally, coupled with innovation in liquid biopsy technology, is anticipated to drive the global liquid biopsy market over the forecast period.

However, expensive medical procedures & a cost-intensive research process involved in liquid biopsy are anticipated to restrain the development of the global liquid biopsy market over the next few years. In addition, liquid biopsy requires a skilled workforce, which is difficult to get. Furthermore, the lack of proper awareness of the availability of different treatment procedures hinders the market's growth. Unfavorable government policies are also impeding the MEA in-vitro diagnostics market demand.

This research report on the North American Liquid Biopsy Market has segmented and sub-segmented the market into the following categories:

By Cancer Type: 

• Lung Cancer
• Pancreatic Cancer
• Leukemia
• Other Visceral Cancers

By Diagnostic Approach: 

• Circulating Tumour cells (CTC)
• Circulating Tumour DNA (ctDNA)
• RNA in exosomes
• Extra-Cellular Vesicles

By End-Users: 

• Reference Laboratories
• Hospital/Physician Laboratories
• Academic and Research Centers
• Other End Users

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the UAE has the highest market share in the Middle East. The government invests in the research and development of innovative products that solely fuel the market demand. Many institutes in this region are researching the liquid biopsy technique. The emergence of the latest techniques and the promotion of quality services in healthcare is enhancing the market growth. 

KEY MARKET PLAYERS:

Some promising companies operating in the MEA Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.